Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, cutaneous lupus erythematosus was associated with significantly impaired quality of life, particularly affecting emotional well-being, compared to other dermatologic and chronic medical conditions.

This review discusses the various common, rare, and unusual skin manifestations of lupus erythematosus and highlights the importance of accurate diagnosis, but it reports no new clinical results.

This review discusses the pathogenesis, clinical presentation, diagnosis, and treatment of cutaneous lupus erythematosus, reporting no new clinical findings.

This article discusses the distinct skin findings associated with lupus erythematosus, noting that some are specific to lupus while others are nonspecific and occur with various diseases; it reports no new results.

This article outlines manifestations of systemic lupus erythematosus, noting rapid joint symptom improvement with corticosteroids and antimalarial drug responsiveness for skin symptoms, and links anti-Ro with photosensitive rash and subacute lupus.

This study found that cutaneous signs such as chilblains and urticaria were notably common in British patients with systemic lupus erythematosus, while subacute cutaneous lesions were less frequent.

This review summarizes the cutaneous manifestations of lupus erythematosus, noting both non-specific and disease-specific lesions, and highlights the role of skin biopsies and treatments available for cutaneous LE.

This article describes the development and validation of a standardized instrument for measuring skin involvement in cutaneous lupus erythematosus, aiming to aid future clinical research and trials.

This study found that the Cutaneous Lupus Disease Area and Severity Index (CLASI) is correlated with both physician-assessed and patient-reported outcomes in cutaneous lupus erythematosus, particularly highlighting concerns about body image in visible areas.

This article reviews clinical and histopathological aspects of cutaneous lupus erythematosus and its treatment, emphasizing the importance of photoprotection and outlining current therapies, but reports no new experimental results.

This review describes the types of skin lesions associated with systemic lupus erythematosus, discussing their histopathological features, serologic associations, pathogenesis, and prognostic implications.

This study suggests that damage to stem cells in the bulge region of hair follicles may contribute to scarring in chronic cutaneous lupus erythematosus.

This study describes the development of the EUSCLE Core Set Questionnaire for cutaneous lupus erythematosus, designed to standardize data collection, facilitate epidemiological analysis, and guide diagnostic and therapeutic strategies across European centers.

This review explores the epidemiology, clinical subtypes, pathology, psychological impact, and treatment options for cutaneous lupus erythematosus, emphasizing the importance of interdisciplinary collaboration and addressing psychological distress to optimize patient outcomes.

This study classified scars in discoid lupus erythematosus patients into six types based on anatomical location and morphology, suggesting early identification might influence more aggressive treatment strategies.

This study found that the quality of life for Japanese lupus erythematosus patients with skin manifestations improved after treatment, though female gender and older age were associated with poorer outcomes in certain quality of life domains.

This review provides detailed recommendations for managing cutaneous lupus erythematosus in primary and secondary care but reports no new clinical results.

This study found that while the CLASI is generally useful for assessing disease activity and damage in cutaneous lupus erythematosus, it may not accurately reflect all subtypes, indicating a need for revision.

This review discusses patient-reported outcomes for health-related quality of life in cutaneous lupus erythematosus and reports no new clinical results; the authors note limited existing research and recommend further studies.

Thalidomide works best for skin lupus not helped by antimalarials, but has many side effects; other treatments are less effective, especially if patients also have systemic lupus.

In this study, a patient with clinically amyopathic dermatomyositis experienced persistent skin issues despite treatment, highlighting questions about type I interferon's role in skin disorders and potential IFN-targeted therapies for cutaneous lupus erythematosus and dermatomyositis.

In this retrospective study of adolescents with recalcitrant cutaneous lupus, lenalidomide treatment resulted in complete or near resolution of skin symptoms within 6 months, while allowing for a reduction in prednisone dosage.

This study reports cases of histopathologically proven cutaneous lupus erythematosus manifesting as frontal fibrosing alopecia, with improvement following treatment with oral hydroxychloroquine and/or intralesional triamcinolone acetonide.

This review discusses topical calcineurin inhibitors for cutaneous lupus erythematosus and reports no new clinical findings; the authors emphasize the need for more comparative studies with corticosteroids.

This article reports a case of Rowell syndrome in a woman with chronic cutaneous lupus erythematosus that appeared to be triggered by COVID-19 infection, suggesting a potential connection.

This study identified six key concerns, including self-consciousness and physical symptoms, among patients with cutaneous lupus erythematosus that should be considered in quality-of-life assessments.

In this report, researchers describe a case of scalp discoid lupus erythematosus unresponsive to topical treatments, where hydroxychloroquine administered at 200 mg/day led to complete resolution of skin lesions in five months.

This chapter reviews the development of skin-specific outcome instruments for autoimmune diseases like cutaneous lupus erythematosus and dermatomyositis, highlighting a need for a broader community-involved process across other diseases but reports no new results.

This report describes two cases of cutaneous lupus erythematosus mimicking alopecia areata, highlighting the importance of considering CLE in the diagnosis of patchy hair loss to prevent scarring alopecia.

In this case report, the authors concluded that cutaneous lupus erythematosus was induced by the PD-1 inhibitor tislelizumab during treatment for metastatic lung adenocarcinoma, despite initial remission and treatment adjustments.